Clinical, toxicological and pharmacological aspects of gemcitabine

Cancer Treatment Reviews

Volumn 22, Issue 1, 1996, Pages 15-31

  Guchelaar, H J ^a   Richel, D J ^a   Van Knapen, A ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CISPLATIN; CREATININE; DOCETAXEL; EDATREXATE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PARACETAMOL; TOPOTECAN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFUSION; CREATININE BLOOD LEVEL; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; EDEMA; ERYTHEMA; FEVER; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALAISE; MELANOMA; NAUSEA; NONHUMAN; OVARY CANCER; PHOSPHORYLATION; REVIEW; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; TOXICOLOGY; VOMITING;

EID: 0029902591     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90014-6     Document Type: Article

References (54)

1. S.B. Kaye Gemcitabine: current status of phase I and phase II trials J. Clin. Oncol. 12 1994 1527 1531
2. V. Heinemann L.W. Hertel G.B. Grindey Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-Arabinofuranosyl-cytosine Cancer Res. 48 1988 4024 4031
3. L.W. Hertel G.B. Boder J.S. Kroin Evaluation of the antitumor activity of gemcitabine (2′,2′-Difluoro-2′-deoxycytidine) Cancer Res. 50 1990 4417 4422
4. D.Y. Bouffard J. Laliberté R.L. Momparler Kinetic studies on 2′,2′-difluorode-oxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase Biochem. Pharmacol. 45 1993 1857 1861
5. D.Y. Boufford L.F. Momparler R.L. Momparler Comparison of antineoplastic activity of 2′,2′-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells Anti-Cancer Drugs 2 1991 49 55
6. V. Heinemann Y.Z. Xu S. Chubb Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation Cancer Res. 52 1992 533 539
7. V. Gandi P. Huang Y.Z. Xu Metabolism and action of 2′,2′-difluorodeoxycytidine: self-potentiation of cytotoxicity 4th edition R.A. Harkness Purine and Pyrimidine Metabolism in Man VII 1991 Plenum Press New York 125 130 part A
8. V. Heinemann Y.Z. Xu S. Chubb Inhibition of ribonucleotide reduction in CCRFCEM cells by 2′,2′-difluorodeoxycytidine Molec. Pharmacol. 38 1990 567 572
9. R. Grunewald H. Kantarjian M.J. Keating Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia Cancer Res. 50 1990 6823 6826
10. A.R. Hanauske D. Degen M.H. Marshall Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units Anti-Cancer Drugs 3 1992 143 146
11. B.J.M. Braakhuis G.A.M.S. van Dongen J.B. Vermorken Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer Cancer Res. 51 1991 211 214
12. V.W.T. Ruiz van Haperen G. Veerman S. Eriksson Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780 Cancer Res. 54 1994 4138 4143
13. J.L. Abbruzzese R. Grunewald E.A. Weeks A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine J. Clin. Oncol. 9 1991 491 498
14. R. Grunewald J.L. Abbruzzese P. Tarassoff Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine Cancer Chemother. Pharmacol. 27 1991 258 262
15. S. Allerheiligen R. Johnson B. Hatcher Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion 4th edition Proc. Am. Soc. Clin. Oncol. 13 1994 136
16. R. Rosso C. Martin Effect of patients age on gemcitabine toxicity profile and efficacy in advanced non-small lung cancer (NSCLC) 4th edition Proc. Am. Soc. Clin. Oncol. 13 1994 366
17. M. Tempero M. Capadano P. Tarassoff Dose escalation of gemcitabine in previously untreated patients with pancreatic adenocarcinoma 4th edition Proc. Am. Soc. Clin. Oncol. 13 1994 218
18. C.F. Pollera A. Ceribelli M. Crecco Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study Ann. Oncol. 5 1994 182 184
19. E.A. Poplin T. Corbett L. Flaterty Difluorodeoxycytidine (dFdC)- gemcitabine: a phase I study Invest. New Drugs 10 1992 165 170
20. H. Anderson N. Thatcher J. Walling A phase I study of 24 hour infusion of gemcitabine in patients with previously untreated, locally advanced, non small cell lung cancer (NSCLC) 4th edition Proc. Am. Soc. Clin. Oncol. 13 1994 348
21. P.J. Dunlop C. Cameron G. Dabouis Phase I dose escalation study of cisplatin in combination with gemcitabine in non-small cell lung cancer 4th edition Proc. Am. Soc. Clin. Oncol. 13 1994 342
22. R. Grunewald H. Kantarjian M. Du Gemcitabine in leukemia; a phase I clinical, plasma, and cellular pharmacology study J. Clin. Oncol. 10 1992 406 413
23. C. Martin B. Lund H. Andersen Gemcitabine weekly schedule better tolerated than twice weekly schedule 4th edition Proc. Am. Soc. Clin. Oncol. 14 1995 433
24. F. Stepherd Y. Cormier R. Burkes Modified continued reassessment methodology (mCRM): a superior way to assess toxiciy in a phase I study of gemcitabine (gem) and cisplatin (CP) for non-small cell lung cancer (NSCLC) 4th edition Proc. Am. Soc. Clin. Oncol. 14 1995 358
25. H. Anderson B. Lund N. Thatcher Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study J. Clin. Oncol. 12 1994 1821 1826
26. R.P. Abratt W.R. Bezwada G. Falkson Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study J. Clin. Oncol. 12 1994 1535 1540
27. R.J. Ginsberg M.G. Kris J.G. Armstrong Cancer of the lung V.T. Devita S. Hellman S.A. Rosenberg Cancer: Principles and Practice of Oncology 4th edition 1993 Lippincott Philadelphia, PA 673 723
28. H. Anderson N. Thatcher J. Walling Gemcitabine and palliation of symptoms in non-small cell lung cancer (NSCLC) Second edition Proc. Am. Soc. Clin. Oncol. 13 1994 367
29. B. Lund M. Ryberg P. Meidahl Peterson Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer Ann. Oncol. 5 1994 852 853
30. F.V. Fossella S.M. Lippman P. Tarassoff Phase I/II study of gemcitabine, an active agent for advanced non-small cell lung cancer (NSCLC) Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 371
31. S.D. Begbie R. Hui J.A. Levi Initial experience with gemcitabine for non-small cell lung cancer (NSCLC) in Australia Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 378
32. R.C. Lilenbaum M.R. Green Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer J. Clin. Oncol. 11 1993 1391 1402
33. F.A. Shepherd Treatment of advanced non-small cell lung cancer Sem. Oncol. 21 suppl 7 1994 7 18
34. K.T. Bastin R. Curley Non-small-cell lung carcinoma; current and future therapeutic management Drugs 49 1995 362 375
35. W.P. Steward D.J. Dunlop C. Cameron Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer (NSCLC) Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 351
36. L. Crinó G. Scagliotti M. Marangola Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC) A phase II study Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 352
37. A.B. Sandler R. Ansari J. McClean A Hoosier oncology group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC) Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 357
38. R.P. Abratt W.R. Bezwoda L. Goedhals A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 375
39. P.A. Bun Jr. The treatment of non-small cell lung cancer: current perpsectives and controversies, future directions Sem. Oncol. 21 suppl 6 1994 49 59
40. R.B. Livingston Current management of unresectable non-small cell lung cancer Sem. Oncol. 21 suppl 10 1994 4 13
41. Y. Cormier E. Eisenhauer A. Muldal Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC) Ann. Oncol. 5 1994 283 285
42. G. Pérez-Manga A. Lluch J. Garcia-Conde Early phase II study of gemcitabine in combination with doxorubicin in advanced breast cancer Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 97
43. C. Sessa S. Aamdal I. Wolff Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of EORTC early clinical trials group Ann. Oncol. 5 1994 471 472
44. K. Christman D. Kelsen L. Saltz Phase II trial of gemcitabine in patients with advanced gastric cancer Cancer 73 1994 5 7
45. D.F. Moore R. Pazdur K. Daugherty Phase II study of gemcitabine in advanced colorectal adenocarcinoma Invest. New Drugs 10 1992 323 325
46. G. Catimel J.B. Vermorken M. Clavel A phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck Ann. Oncol. 5 1994 543 547
47. W.C. Mertens E.A. Eisenhauer M. Moore Gemcitabine in advanced renal cell carcinoma Ann. Oncol. 4 1993 331 332
48. B. Lund O.P. Hansen K. Theilade Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients J. Natl. Cancer Inst. 86 1994 1530 1533
49. M. Kaufmann T. Bauknecht W. Jonat Gemcitabine (gem) is cisplatin-resistant ovarian cancer Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 272
50. M.J. Millward D. Rischin G.C. Toner Activity of gemcitabine in ovarian cancer patients resistant to paclitaxel Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 277
51. W. Stadler T. Kuzel D. Raghavan A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 241
52. M.L. Rothenberg H.A. Burris J.S. Andersen Gemcitabine: effective palliative therapy for pancreas cancer in patients failing 5-FU Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 198
53. M. Moore J. Andersen H. Burris A randomized trial of gemcitabine (gem) versus 5-FU as first-line therapy in advanced pancreatic cancer Second edition Proc. Am. Soc. Clin. Oncol. 14 1995 199
54. D.S. Shewach T.M. Hahn E. Chang Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells Cancer Res. 54 1995 3218 3223